CONMED Corporation

Oct 1, 2026

CONMED Corporation to Report Third Quarter 2026 Financial Results on October 28, 2026

CONMED Corporation has announced it will report its third quarter 2026 financial results on October 28, 2026. The report will be released after market close, followed by a conference call at 4:30 p.m. ET to discuss the results. This event provides an opportunity for stakeholders to engage with the company's management.

Aug 26, 2026

CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference

CONMED Corporation has announced its participation in the Wells Fargo 21st Annual Healthcare Conference scheduled for September 8-10, 2026. The company's management will engage in a fireside chat on September 9th at 1:30 p.m. Eastern Time. A live audio webcast will be available on the investor relations website.

CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance

CONMED Corporation reported its financial results for the second quarter of 2026, showing a slight increase in sales compared to the previous year. The company also provided an updated financial guidance for the full year, indicating a positive outlook. Notably, organic net sales rose by 6.0% after excluding the impact of strategic exits from GI product offerings.

Jul 22, 2026

CNMDFDA Updates

CONMED Corporation Announces Expanded Indication for the FDA Cleared AirSeal® Robotic Solution for Use with the Intuitive da Vinci 5 Hex Cannula

CONMED Corporation has announced an expanded indication for its AirSeal Robotic Solution, which is now approved for use with Intuitive's 8 mm hex cannulas as part of the da Vinci 5 platform. This addition complements the existing indication for round cannulas, enhancing the product's compatibility with various da Vinci robotic systems. The expansion aims to improve surgical efficiency and patient outcomes.

Jul 20, 2026

CONMED Corporation to Participate in the Society of Robotic Surgery Annual Meeting

CONMED Corporation will participate in the Society of Robotic Surgery Annual Meeting scheduled for July 23-26, 2026, in Fort Lauderdale, FL. Professor Nikhil Vasdev will present findings from a randomized controlled trial focusing on intraoperative and post-operative pain levels. This participation underscores CONMED's dedication to advancing robotic surgery techniques.

Jul 2, 2026

CONMED Corporation to Report Second Quarter 2026 Financial Results on July 29, 2026

CONMED Corporation is scheduled to report its financial results for the second quarter of 2026 on July 29, 2026. This announcement is part of the company's regular financial reporting cycle. Further details regarding the performance metrics will be disclosed at that time.

Jun 17, 2026

CONMED Corporation Appoints John E. Gallagher as Chief Financial Officer

CONMED Corporation has announced the appointment of John E. Gallagher as its new Chief Financial Officer. This decision is part of the company's strategy to enhance its financial leadership. Gallagher brings extensive experience in finance and management to the role, which is expected to benefit the organization moving forward.

May 20, 2026

CONMED Corporation Appoints Celine Martin and Jeff Mirviss to its Board of Directors

CONMED Corporation has appointed Celine Martin and Jeff Mirviss to its Board of Directors. This strategic move aims to enhance the company's leadership team. The appointments reflect CONMED's commitment to strengthening its governance and oversight capabilities.

Apr 29, 2026

CONMED Corporation Announces First Quarter 2026 Financial Results

CONMED Corporation reported its first quarter 2026 financial results, showing a slight decline in sales of 1.3% year-over-year, primarily due to the exit of certain GI products. However, the company experienced growth in international revenue and improved adjusted earnings per share. Management has raised its full-year revenue growth outlook, reflecting confidence in its higher-margin areas.

Apr 2, 2026

CONMED Corporation to Announce First Quarter 2026 Financial Results on April 29, 2026

CONMED Corporation has scheduled the announcement of its financial results for the first quarter of 2026 on April 29, 2026. This announcement is part of the company's regular financial reporting process. Further details regarding the financial performance will be provided at that time.

Jan 12, 2026

J.P. Morgan 44 th Annual Healthcare Conference Pat J. Beyer President and Chief Executive Officer Todd W. Garner Executive Vice President and Chief Financial Officer January 12 th , 2026 Forward - Looking Information Thi

At the J.P. Morgan 44th Annual Healthcare Conference, CONMED's management discussed forward-looking statements regarding the company's financial outlook and product innovations. They presented insights into expected revenue growth across various sectors, particularly in sports medicine and general surgery. The emphasis was placed on the growth potential of AirSeal technology and BioBrace implants, which are gaining traction due to legislative support and clinical validation. However, risks associated with forward-looking indicators were acknowledged, including uncertainties in projections related to financial performance.

CONMED Corporation Announces Strategic Exit from Gastroenterology Product Lines

CONMED Corporation announced a strategic exit from its gastroenterology product lines, effective January 1, 2026. This decision aims to optimize their portfolio and focus on core areas such as minimally invasive surgery and orthopedic soft tissue repair. The company concluded its distribution agreement with Gore for the VIABIL stent earlier than planned. Despite this transition, CONMED has reaffirmed its revenue and EPS guidance for 2025, indicating confidence in its core business growth.

Sep 9, 2025

CONMED Corporation Adds Kim Kelderman to its Board of Directors

CONMED Corporation has appointed Kim Kelderman to its Board of Directors, effective September 8, 2025. Kelderman brings a wealth of experience from roles at Bio-Techne and Thermo Fisher Scientific, where he led various significant business segments. The leadership at CONMED is optimistic about the value his insights and track record in life sciences will bring as they focus on delivering stakeholder value and achieving their long-term vision.

Jul 7, 2025

Martha Aronson to Step Down from CONMED Board of Directors Following Appointment as President and Chief Executive Officer of Merit Medical Systems, Inc.

Martha Aronson will step down from the CONMED Corporation Board of Directors to become the President and CEO of Merit Medical Systems, Inc. Her resignation is effective July 7, 2025, following her significant contributions since joining the board in February 2016. During her tenure, Aronson has focused on improving strategic growth and governance excellence, playing a key role in guiding the company. The President and CEO of CONMED expressed gratitude for her service and wished her success in her new position.

Apr 30, 2025

CONMED Corporation Announces First Quarter 2025 Financial Results

CONMED Corporation has announced its financial results for the first quarter of 2025, highlighting a positive start to the year. The company expects its full-year reported revenue to be between $1.350 billion and $1.378 billion, an increase from previous guidance. Additionally, the adjusted diluted net earnings per share for 2025 are projected to rise, suggesting strong operational performance. However, potential tariff implications could negatively impact earnings later in the year.

Feb 25, 2025

CONMED Corporation Adds Mark Kaye to its Board of Directors

CONMED Corporation has announced the appointment of Mark Kaye to its Board of Directors, effective February 24th, 2025. Kaye brings significant expertise in finance, accounting, risk management, and corporate governance, which the board believes will enhance the company’s strategic direction. With a background as CFO at Elevance Health and Moody’s Corporation, Kaye is expected to contribute valuable insights that will benefit CONMED's growth opportunities.

Feb 5, 2025

CONMED Corporation Announces Fourth Quarter and Full-Year 2024 Financial Results

CONMED Corporation reported its financial results for the fourth quarter and full year ended December 31, 2024, showing solid growth in sales and earnings. The company highlighted improved profitability in the fourth quarter despite challenges with supply chain issues. For 2025, CONMED estimates revenue between $1.344 billion and $1.372 billion, indicating a modest growth outlook. However, the business anticipates currency headwinds and potential impacts from recent tariffs. Management remains focused on enhancing operations to strengthen the foundation for future growth.

Jan 13, 2025

J.P. Morgan 43rd Annual Healthcare Conference Forward-Looking Information This presentation may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, whic

During the J.P. Morgan 43rd Annual Healthcare Conference, CONMED presented forward-looking information that may involve various risks and uncertainties impacting its performance. The company's objectives include long-term growth and enhancing shareholder value through strategic initiatives. CONMED highlighted its focus on evolving its product offerings and expanding market share in attractive segments such as orthopedics and general surgery. While management expressed optimism about future growth, they also indicated the challenges posed by different market conditions and competition.

Oct 30, 2024

CONMED Corporation Announces Third Quarter 2024 Financial Results

CONMED Corporation announced its third quarter financial results for 2024, indicating a revenue forecast of $1.300 billion to $1.305 billion. The company reported net income of $48.984 million for the quarter, significantly up from the previous year's $15.837 million. While the overall performance was in line with expectations, the full-year revenue guidance was lowered compared to prior projections. The company also highlighted operational challenges due to disruption from hurricanes affecting their Southeast locations.

Oct 4, 2024